Released Nov 8, 2016, after the close
10-Q filed Nov 9, 2016, 40 days after period end · 0001493152-16-014680
Q3 2016 · 10-Q
Revenue$5.44M$5.44M −10.5% vs Q3 2015+0.7% vs Q2 2016
Net Income-$573.00K-$573.00K N/M vs Q3 2015N/M vs Q2 2016
EPS Diluted-$0.31-$0.31 N/M vs Q3 2015N/M vs Q2 2016
Operating Income-$414,000N/M
Operating Cash Flowderived-$41,000N/M
Free Cash Flowderived-$56,000N/M
Margins · derived
Operating margin-7.6%+14.0 pt vs Q3 2015
Net margin-10.5%+11.6 pt vs Q3 2015
What the release said
The release
Same quarter
| Metric | Q3 2016 | Q3 2015 | Q3 2014 | Q3 2013 |
|---|---|---|---|---|
| Revenue | $5.44M | $6.08M | $6.01M | $5.53M |
| Net Income | -$573.00K | -$1.35M | -$1.32M | -$234.00K |
| EPS Diluted | -$0.31 | -$0.73 | -$0.01 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR